Achieving optimal beta1-blockade with metoprolol CR/Zok

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Drug Delivery Systems

Background:

• Metoprolol is a selective beta1-receptor blocker used for cardiovascular conditions.
• Achieving stable plasma concentrations with immediate-release formulations can be challenging.
• Controlled-release formulations aim to improve therapeutic outcomes and patient compliance.

Purpose of the Study:

• To evaluate the pharmacokinetic and pharmacodynamic profile of metoprolol controlled release/once daily (CR/Zok).
• To assess the efficacy and tolerability of metoprolol CR/Zok in patients with chronic heart failure.
• To compare metoprolol CR/Zok with immediate-release formulations regarding plasma concentration fluctuations and beta-blockade.

Main Methods:

• Metoprolol CR/Zok is a multi-unit formulation with microcapsules designed for sustained drug release.
• The formulation delivers metoprolol succinate at a near-constant rate for approximately 20 hours.
• Pharmacokinetic and pharmacodynamic parameters were assessed, considering metoprolol's half-life for 24-hour coverage.

Main Results:

• Metoprolol CR/Zok ensures an even plasma concentration over 24 hours with once-daily dosing.
• This formulation significantly decreases plasma fluctuations compared to immediate-release versions.
• Consistent and vital beta1-blockade is maintained for 24 hours across various doses (12.5-200 mg).
• Cardioselectivity is maintained even at higher doses.
• The MERIT-HF study demonstrated improved well-being in chronic heart failure patients.

Conclusions:

• Metoprolol CR/Zok offers a reliable and effective 24-hour beta1-blockade through a convenient once-daily regimen.
• The formulation's design minimizes plasma concentration peaks and troughs, enhancing therapeutic consistency.
• Metoprolol CR/Zok is well-tolerated and shows benefits in improving patient well-being, particularly in chronic heart failure management.